EGFR and ovarian cancer: This study identified a novel role of ADAM17 in promoting chemo resistance in ovarian cancer and it provides evidence that ADAM17 and related signaling pathways including the EGFR and it ́s ligands could function as effective targets for combinatorial therapy approaches of this still devastating disease.